Revenue and Profit Performance - The group's revenue for the six months ended December 31, 2023, was approximately HKD 49,700,000, a decrease of about 26.6% compared to HKD 67,700,000 for the same period last year[8]. - Profit attributable to equity holders for the same period was approximately HKD 17,100,000, down approximately 44.1% from HKD 30,600,000 year-on-year[15]. - Revenue from healthcare staffing solutions was approximately HKD 40,700,000, a decrease of about 29.8% from HKD 58,000,000 in the previous year, primarily due to reduced demand for COVID-19 testing services[8]. - For the six months ended December 31, 2023, customer contract revenue was HKD 49,703,000, a decrease of approximately 26.6% from HKD 67,689,000 in the same period last year[44]. - Total comprehensive income for the period was HKD 15,836,000, down from HKD 30,022,000 year-on-year, representing a decline of approximately 47.3%[45]. - The operating profit for the six months ended December 31, 2023, was HKD 21,091,000, a decrease of about 45.4% compared to HKD 38,667,000 in the previous year[44]. - The company reported a basic and diluted earnings per share of 4.28 HKD cents, down from 7.65 HKD cents in the same period last year, reflecting a decline of approximately 44.5%[45]. - The company's profit before tax for the six months ended December 31, 2023, was approximately HKD 21 million, down approximately 44.9% from about HKD 38.1 million for the same period in 2022[56]. - The total comprehensive income for the six months ended December 31, 2023, was HKD 15.836 million, down from HKD 30.039 million for the same period in 2022[59]. - The net loss for the period was approximately HKD 1,900,000 (for the six months ended December 31, 2022: net loss of HKD 700,000)[150]. Cash Flow and Financial Position - Cash and bank balances as of December 31, 2023, were approximately HKD 74,700,000, down from HKD 93,300,000 as of June 30, 2023[18]. - The net cash used in operating activities for the six months ended December 31, 2023, was HKD (501,000), compared to HKD 5.9 million generated in the same period in 2022[49]. - The net cash used in investing activities for the six months ended December 31, 2023, was HKD (1.835 million), compared to HKD 3.128 million generated in the same period in 2022[49]. - The net cash used in financing activities for the six months ended December 31, 2023, was HKD (16.212 million), compared to HKD (22.280 million) in the same period in 2022[49]. - Cash and cash equivalents totaled HKD 74,723,000, down from HKD 93,269,000, a decrease of 19.8%[82]. - The company declared an interim dividend of HKD 20.123 million for the six months ended December 31, 2023, equivalent to HKD 0.05 per share[56]. - The company declared an interim dividend of HKD 0.05 per share, totaling HKD 20,123,000 based on the number of shares issued as of the announcement date[176]. - The group maintained a healthy liquidity position as of December 31, 2023, with working capital needs met through equity and cash generated from operations[122]. Expenses and Cost Management - Employee benefits expenses for the period were approximately HKD 12,200,000, a decrease of about HKD 1,200,000 compared to HKD 13,400,000 for the same period last year[13]. - Total expenses reduced to HKD 155,490,000 from HKD 218,749,000, a decrease of 28.9%[72]. - Other operating expenses for the period were approximately HKD 4,900,000 (for the six months ended December 31, 2022: HKD 6,000,000), a decrease of approximately HKD 1,100,000[151]. - Total employee costs for the period (including director remuneration) were approximately HKD 12,200,000 (for the six months ended December 31, 2022: HKD 13,400,000)[162]. Trade and Receivables - Trade payables increased from approximately HKD 24,600,000 as of June 30, 2023, to approximately HKD 26,200,000 as of December 31, 2023, representing a 6.5% increase year-on-year[16]. - Trade receivables increased to HKD 52,834,000 from HKD 46,272,000, representing an increase of approximately 14.5%[46]. - Trade receivables increased from approximately HKD 46,300,000 on June 30, 2023, to approximately HKD 52,800,000 on December 31, 2023, an increase of about HKD 6,500,000[121]. - The group did not recognize any provisions for trade receivables during the period, consistent with the previous year[121]. Strategic Initiatives and Future Outlook - The group aims to explore business opportunities and strategic partnerships to expand its operations beyond the current scale and position[10]. - The board remains optimistic about the continued growth of the company's core business in the coming years, driven by an aging population and increasing demand for healthcare staffing solutions[113]. - The group aims to solidify its market position and explore profitable long-term business growth opportunities[113]. Assets and Liabilities - As of December 31, 2023, total assets amounted to HKD 327,891,000, a decrease from HKD 346,828,000 as of June 30, 2023[47]. - The company had no significant or substantial debt as of December 31, 2023, with a capital debt ratio of zero[35][39]. - As of December 31, 2023, the total outstanding bank borrowings amounted to HKD 64,400,000, all of which are short-term loans[125]. - The group has no significant capital commitments as of December 31, 2023[127]. Financial Income and Investments - Financial income from short-term bank deposits increased to approximately HKD 856,000 from about HKD 22,000 in the previous year, an increase of approximately HKD 834,000[14]. - Financial income for the period was HKD 856,000, significantly up from HKD 22,000 in the previous year[44]. - The group did not sell any financial assets during the period but acquired financial assets worth approximately HKD 2,500,000, maintaining its primary investment objective of increasing excess cash and improving yield[85]. - The actual annual interest rate for bank deposits ranged from 4.95% to 5.36% as of December 31, 2023, compared to 1% to 4.8% on June 30, 2023[140]. Market and Operational Insights - The group’s major business operations are primarily located in Hong Kong, with all revenue generated from external customers in Hong Kong[95]. - Approximately 29,500 registered healthcare personnel were associated with the group as of December 31, 2023[144]. - The group’s cash and cash equivalents are primarily denominated in HKD and USD, minimizing foreign currency risk[124]. - Revenue from institutional staffing solutions decreased by approximately 39.7% to HKD 27,300,000 (for the six months ended December 31, 2022: HKD 45,300,000)[147]. - Revenue from private caregiver staffing services slightly decreased by approximately 5.5% to HKD 13,400,000 (for the six months ended December 31, 2022: HKD 12,700,000)[147]. - The company has not adopted new accounting standards that would significantly impact its accounting policies during the reporting period[92]. - The board believes that the global capital markets will continue to face severe challenges in 2024[145].
百本医护(02293) - 2024 - 中期业绩